SILO (SILO Pharma) Insider Ownership: 54.23 % (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SILO SILO Pharma Inc SILO
42 GF Score
Price $2.10
GF Value $3.44
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SILO Pharma Insider Ownership?

SILO Pharma SILO 42 Insider Ownership is 54.23 % as of Sep. 11, 2026. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SILO Pharma's insider ownership is 54.23%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SILO Pharma's Institutional Ownership is 11.42%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SILO Pharma's Float Percentage Of Total Shares Outstanding is 91.34%.

SILO Pharma Insider Ownership Historical Data

* Premium members only.

The historical data trend for SILO Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SILO Pharma Insider Ownership Chart

SILO Pharma Historical Data

The historical data trend for SILO Pharma can be seen below:

2018-02-28 2018-03-31 2018-04-30 2018-05-31 2018-06-30 2018-07-31 2018-08-31 2018-09-30 2018-10-31 2018-11-30
Insider Ownership 54.23 54.23 54.23 54.23 54.23 54.23 54.23 54.23 54.23 54.23
SILO
42GF Score
SILO Pharma Inc SILO
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SILO Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 54.23 % mean?
SILO Pharma (SILO) has a Insider Ownership of 54.23 % as of Sep. 11, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on SILO Pharma and its competitors.
Is SILO Pharma's Insider Ownership too high?
SILO Pharma's current Insider Ownership is 54.23 %. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's Insider Ownership compare to ELAB and GLMD?
SILO Pharma's Insider Ownership of 54.23 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on SILO Pharma and its competitors. SILO Pharma's current Insider Ownership is 54.23 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current Insider Ownership is 54.23 %. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For SILO Pharma (SILO), the current Insider Ownership is 54.23 % as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SILO Pharma (SILO) Overvalued in 2026?

Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued. The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44. GuruFocus considers SILO Pharma to be Possible Value Trap.

Key valuation signals for SILO:

  • Insider Ownership: 54.23 %
  • GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SILO Pharma Business Description

Address 677 N. Washington Boulevard, Sarasota, FL, USA, 34236
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score

Get the complete analysis for SILO

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$3.44
GF Value